Compare · BDX vs KIDS
BDX vs KIDS
Side-by-side comparison of Becton Dickinson and Company (BDX) and OrthoPediatrics Corp. (KIDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BDX and KIDS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- BDX is the larger of the two at $43.32B, about 104.2x KIDS ($415.9M).
- BDX has been more active in the news (9 items in the past 4 weeks vs 3 for KIDS).
- BDX has more recent analyst coverage (25 ratings vs 8 for KIDS).
- Company
- Becton Dickinson and Company
- OrthoPediatrics Corp.
- Price
- -
- -
- Market cap
- $43.32B
- $415.9M
- 1M return
- -
- -0.40%
- 1Y return
- -
- -25.64%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2017
- News (4w)
- 9
- 3
- Recent ratings
- 25
- 8
Becton Dickinson and Company
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products and systems; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for high-throughput single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. Becton, Dickinson and Company was founded in 1897 and is based in Franklin Lakes, New Jersey.
OrthoPediatrics Corp.
OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company offers trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc tibia, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, Spica Tables, RESPONSE Spine systems, Bandloc, Pediguard, Pediatric Nailing Platform, Femur system, Orthex, QuickPack, and ApiFix Mid-C system. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Latest BDX
- BD Earns Industry Top Honors for Transparency, Resiliency and Partnership
- Goldman resumed coverage on Becton Dickinson with a new price target
- Becton Dickinson and Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- BD to Announce Financial Results for its Second Quarter of Fiscal 2026
- Rick Byrd to Retire from BD
- For Women Managing Nighttime Incontinence, Better Sleep and Comfort Start with BD® PureWick® Urine Collection System
- BD Delivers Next‑Generation TIPS Innovation to Advance Portal Hypertension Care Across the European Union
- When Every Beat Matters, BD Helps Clinicians Eliminate Blind Spots with Continuous, Noninvasive Blood Pressure Insight
- SEC Form 4 filed by Neal Shana Carol
- Becton Dickinson and Company filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest KIDS
- SEC Form DEF 14A filed by OrthoPediatrics Corp.
- SEC Form DEFA14A filed by OrthoPediatrics Corp.
- OrthoPediatrics Corp. to Report First Quarter Financial Results on April 30, 2026
- OrthoPediatrics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- OrthoPediatrics to Participate in the 25th Annual Needham Virtual Healthcare Conference
- COO and CFO Hite Fred was granted 77,405 shares and sold $224,129 worth of shares (12,993 units at $17.25), increasing direct ownership by 30% to 277,477 units (SEC Form 4)
- Pres. Trauma & Def. Correction Hauser Joseph W was granted 65,700 shares and sold $148,281 worth of shares (8,596 units at $17.25), increasing direct ownership by 41% to 194,767 units (SEC Form 4)
- President and CEO Bailey David R sold $336,979 worth of shares (19,535 units at $17.25), decreasing direct ownership by 6% to 298,020 units (SEC Form 4)
- President of Scoliosis Odle Gregory A sold $145,469 worth of shares (8,433 units at $17.25) and was granted 47,380 shares, increasing direct ownership by 26% to 187,735 units (SEC Form 4)
- General Counsel and Secretary Gerritzen Daniel J was granted 47,380 shares and sold $148,592 worth of shares (8,614 units at $17.25), increasing direct ownership by 35% to 149,533 units (SEC Form 4)